Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
21 hedge funds and large institutions have $7.96M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 20 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
35% less capital invested
Capital invested by funds: $12.2M → $7.96M (-$4.2M)
49% less funds holding
Funds holding: 41 → 21 (-20)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHA
First Horizon Advisors
Memphis,
Tennessee
|
+$880K |
| 2 |
Millennium Management
New York
|
+$666K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.1K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4.28K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$327K |
| 2 |
D.E. Shaw & Co
New York
|
-$99K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$57K |
| 4 |
Renaissance Technologies
New York
|
-$57K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$54K |
ONCT Hedge Fund Activity: Q4 2016 in Review
21 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2016, worth a combined $7.96M — down 35% from $12.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ONCT and 0 opened new positions — a net loss of 20 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was First Horizon Advisors, adding an estimated $880K. The largest seller was BVF Inc, cutting an estimated $327K.
- 21 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2016, down from 41 in Q3 2016.
- Funds reported $7.96M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2016, down 35% quarter-over-quarter.
- 0 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2016 and 20 closed out, a net change of -20 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2016 was First Horizon Advisors, an estimated $880K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2016 was BVF Inc, an estimated $327K sold.
Based on aggregated 13F filings for Q4 2016.